Navigation Links
Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
Date:9/17/2012

HAYWARD, Calif., Sept. 17, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today provided an update on regulatory discussions for the global development of blisibimod.  End of Phase 2 discussions with the US Food and Drug Administration (FDA) have been completed and will allow for the submission of Phase 3 protocols and the initiation of registration studies.  Earlier in 2012, Anthera received a written response from the European Medicines Agency (EMA) providing similar development feedback for the blisibimod program.

"We appreciate the FDA's rapid response to our development proposal for blisibimod. We will incorporate their comments and begin the initiation of our Phase 3 lupus program," said Paul F. Truex, Anthera's President and CEO.  "The PEARL-SC clinical study provided meaningful insight into the importance of selecting an appropriate patient population while also defining a meaningful endpoint.  We are grateful the FDA found this approach to be acceptable for further study and look forward to bringing blisibimod one step closer to patients in need."

The Phase 3 studies (CHABLIS-SC1 and CHABLIS-SC2) will be multicenter, placebo-controlled, randomized, double-blind studies designed to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with clinically active SLE (SELENA-SLEDAI > 10) who have not achieved optimal resolution of their disease with corticosteroid use.  Patients will be treated in the controlled part of each study for 52 weeks after which they will have the option to receive additional treatment as part of an open-label, long-term, follow-up safety study. The primary endpoint of the CHABLIS studies will be a Systemic Lupus Eryth
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
2. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
3. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
4. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
5. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
6. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
7. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
8. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
9. Anthera Announces First Quarter 2012 Financial Report and Conference Call
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. Merz, Inc. Announces Cynthia Schwalm as Vice President, Neurology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  Cyberonics, Inc. (NASDAQ: CYBX ) today ... Quarterly highlights 1   Operating results ... first quarter of fiscal 2014, and other achievements, include: ... of 6.8%; , Strong international net sales of $13.2 ... , U.S. net product sales reached a new high ...
(Date:8/21/2014)... CHESTERBROOK, Pa. , Aug. 21, 2014 /PRNewswire/ ... AUXL ), a specialty biopharmaceutical company, today announced ... study of collagenase clostridium histolyticum (or CCH) for ... known as cellulite. In the Phase 2a trial, ... (0.48mg) and high (0.84mg)) showed an improvement in ...
(Date:8/20/2014)... , Aug. 20, 2014  The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Kentucky blocked the sale of ...
Breaking Medicine Technology:Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Kentucky's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... Goodwin Biotechnology, Inc. (GBI) and OncoMax, LLC, a ... cell line engineering and manufacturing of a monoclonal antibody ... will be engineered by GBI,s collaborative partner, and then ... producer and manufacture the monoclonal antibody for use and ...
... Eppendorf AG has licensed patents covering ... for use in their thermal cyclers, including US patent ... its Eppendorf Mastercycler® pro gradient, Mastercycler gradient and Mastercycler ... Hamburg, Germany, develops, produces and distributes instruments and consumables ...
Cached Medicine Technology:Goodwin Biotechnology and OncoMax, a Maxwell Biotech Portfolio Company, Announce a "Bench-to-Clinic" Collaboration for an Important Advance in Oncology 2Goodwin Biotechnology and OncoMax, a Maxwell Biotech Portfolio Company, Announce a "Bench-to-Clinic" Collaboration for an Important Advance in Oncology 3
(Date:8/21/2014)... Top10BestSEOHosting.com has compared many professional SEO hosting companies and ... most reliable suppliers for webmasters who want to buy ... in websites in recent years, and the new demand ... web hosting companies that offer a variety of different ... providing hosting solutions to thousands of business and personal ...
(Date:8/21/2014)... August 11: – Robin William’s suicide was ... hanging, likely due to long-term depression. , ... Vocal Profiling investigator, appeared on the Joyce Riley Power ... hoping to help people understand why he chose not ... were proposed in terms of BioAcoustic Biology: Using vocal ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 The costs paid ... continue to rise, according to insurer data. The Quotes Pros ... in real time using its tools at http://quotespros.com . ... the company homepage connects with providers offering multiple coverage packages ... are promoted to the public are now easier to compare ...
(Date:8/21/2014)... August 21, 2014 Today, Zane Benefits, ... on the premium tax credits in 2015. , According ... As part of the Affordable Care Act (ACA), premium ... purchase individual health insurance through the Health Insurance Marketplaces. ... eligibility and the amount of the tax credits, updated ...
(Date:8/21/2014)... in the coronary arteries of chronic kidney disease patients ... according to a new study in the Journal ... ). Researchers at the Johns Hopkins Bloomberg School of ... commonly used measures of subclinical atherosclerosis in predicting the ... , Approximately 50 percent of all patients with chronic ...
Breaking Medicine News(10 mins):Health News:Best SEO Hosting Suppliers in the Global Market Recommended by Top10BestSEOHosting.com 2Health News:Robin Williams: What he could not bear to face 2Health News:Robin Williams: What he could not bear to face 3Health News:Dental Insurance Now Quoted for Families Online at Insurer Portal 2Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2
... Sept. 12 GSI Securitization,Inc. (Pink Sheets: GSIEF) ... "GSI is engaged in a,project with nine separate ... and funding for healthcare accounts receivable. This is ... for funding of receivables in the,$2-trillion+ healthcare market. ...
... If you,re one of the,millions of Texans who ... your handkerchief: Allergy researchers at Presbyterian Hospital of,Dallas say ... decades. "The unusually wet weather this summer means ... for lots of people," said Gary Gross, MD, an,allergist ...
... 2007) -- The University of South Floridas global health ... AIDS has been strengthened with a $1.36-million research training ... USF Health received the five-year grant Sept. 11 from ... training program focused on the biomedical, behavioral, cultural and ...
... Sept. 12 Navitas Cancer Rehabilitation Centers,of ... providing integrated and,comprehensive cancer rehabilitation services, is ... new center in Albuquerque, New Mexico. The ... New Mexico Oncology,Hematology Consultants, Ltd., (NMOHC) the ...
... aid children in crucial days after trauma, developers say ... now allows doctors to monitor blood flow through the ... death in children with head injuries. , Brain trauma ... States. Almost 475,000 children suffer brain injuries annually, according ...
... depends on the steady work of a vital gene that ... School cancer geneticists have found. Their research reveals an ... system, and opens novel strategies for targeting the gene, which ... , We have identified a new pathway that is essential ...
Cached Medicine News:Health News:Allergists at Presbyterian Hospital of Dallas Say This Year's Fall Allergy Season Could be Worst in Decades 2Health News:Global Health Project targets reducing AIDS among India's adolescents 2Health News:Navitas Opens New Cancer Rehabilitation Center in Albuquerque in Conjunction With New Mexico Cancer Centers 2Health News:Navitas Opens New Cancer Rehabilitation Center in Albuquerque in Conjunction With New Mexico Cancer Centers 3Health News:Imaging Software Helps Track, Treat Injured Brains 2Health News:Unique role for blood formation gene identified 2
... Portex® Thermovent® T helps provide protection to the ... small and extremely lightweight making it ideal for ... a high rate of heat and moisture recovery, ... ,All HMEs and filters have ISO standard ...
... Intersurgical Incorporated manufactures high ... and moisture exchangers, ventilator ... hand-held nebulizers and an ... and connectors for anesthesia ...
... The Ulti-Mist™ HME product line has the ... pediatrics to adults and from intubated patients ... superior humidification for both anesthesia and critical ... HME/Filters provide maximum protection for patients and ...
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Medicine Products: